Lexicon Pharmaceuticals Announces Material Agreement & Financial Updates
Ticker: LXRX · Form: 8-K · Filed: Mar 11, 2024
Sentiment: neutral
Topics: material-agreement, financial-results, equity-sale, corporate-action
Related Tickers: LXRX
TL;DR
Lexicon inked a deal, dropped financial results, and made some corporate changes. Big moves ahead?
AI Summary
Lexicon Pharmaceuticals, Inc. announced on March 6, 2024, that it entered into a material definitive agreement. The company also reported its results of operations and financial condition. Additionally, Lexicon disclosed unregistered sales of equity securities and amendments to its articles of incorporation or bylaws, along with a change in its fiscal year.
Why It Matters
This 8-K filing indicates significant corporate actions, including a new agreement and financial reporting, which could impact investor understanding of the company's current standing and future direction.
Risk Assessment
Risk Level: medium — The filing details a material definitive agreement and unregistered sales of equity, which can introduce financial and operational risks.
Key Players & Entities
- Lexicon Pharmaceuticals, Inc. (company) — Registrant
- March 6, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement entered into by Lexicon Pharmaceuticals?
The filing states that Lexicon Pharmaceuticals, Inc. entered into a material definitive agreement on March 6, 2024, but the specific details of this agreement are not provided in this summary.
What financial information is being reported in this 8-K filing?
The filing indicates that Lexicon Pharmaceuticals, Inc. is reporting its results of operations and financial condition.
Were there any unregistered sales of equity securities by Lexicon Pharmaceuticals?
Yes, the filing explicitly lists 'Unregistered Sales of Equity Securities' as an item of information being reported by Lexicon Pharmaceuticals, Inc.
Did Lexicon Pharmaceuticals amend its articles of incorporation or bylaws?
Yes, the filing includes 'Amendments to Articles of Incorporation or Bylaws' as a reported item, suggesting changes were made.
Is there a change in Lexicon Pharmaceuticals' fiscal year?
Yes, the filing lists 'Change in Fiscal Year' as one of the items of information being reported by Lexicon Pharmaceuticals, Inc.
Filing Stats: 1,898 words · 8 min read · ~6 pages · Grade level 11.7 · Accepted 2024-03-11 07:26:32
Key Financial Figures
- $0.001 — ich registered Common stock, par value $0.001 LXRX The Nasdaq Global Select Marke
- $0.01 — eferred Stock of the Company, par value $0.01 per share (the " Preferred Stock "), at
- $108.50 — the " Preferred Stock "), at a price of $108.50 per share in a private placement (the "
- $250 m — roceeds to the Company of approximately $250 million, before deducting placement agent
Filing Documents
- d766707d8k.htm (8-K) — 41KB
- d766707dex101.htm (EX-10.1) — 229KB
- d766707dex102.htm (EX-10.2) — 26KB
- d766707dex991.htm (EX-99.1) — 67KB
- d766707dex992.htm (EX-99.2) — 10KB
- g766707g0307173624741.jpg (GRAPHIC) — 3KB
- g766707g0308020125319.jpg (GRAPHIC) — 3KB
- 0001193125-24-064310.txt ( ) — 597KB
- lxrx-20240306.xsd (EX-101.SCH) — 3KB
- lxrx-20240306_lab.xml (EX-101.LAB) — 18KB
- lxrx-20240306_pre.xml (EX-101.PRE) — 11KB
- d766707d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits (d)Exhibits. Exhibit Number Description 10.1+ Preferred Stock Purchase Agreement, dated as of March 11, 2024, among Lexicon Pharmaceuticals, Inc. and the purchasers party thereto. 10.2 Fifth Amendment to Loan and Security Agreement, dated March 6, 2024, with Oxford Finance, LLC and the lenders listed therein 99.1 Press Release (Earnings), dated March 11, 2024. 99.2 Press Release (Announcement of Private Placement), dated March 11, 2024. EX-104 Cover Page Interactive Data File (embedded within the Inline XBRL document) + Certain schedules and similar attachments have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant undertakes to furnish supplemental copies of any of the omitted schedules upon request by the SEC. In accordance with Item 601(b)(2)(ii) of Regulation S-K, certain information (indicated by "[**]") has been excluded from this exhibit because it is both not material and would likely cause competitive harm to the Company if publicly disclosed. 4
Signatures
Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Lexicon Pharmaceuticals, Inc. Date: March 11, 2024 By: /s/ Brian T. Crum Brian T. Crum Senior Vice President and General Counsel